CommercialCoverageMedium impact
Intensity-Modulated Radiotherapy (IMRT): Central Nervous System Tumors
Blue Cross & Blue Shield of Mississippi·MS · Neurosurgery, Oncology, Radiology·Medical Policy
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield Mississippi has updated their IMRT policy for central nervous system tumors, establishing specific medical necessity criteria when tumors are near critical brain structures and 3D conformal radiotherapy cannot meet dose tolerance limits. The policy also covers hippocampal-avoiding IMRT for brain metastases with specific distance and survival requirements.
Action Required
Immediately: Review current IMRT cases for CNS tumors to ensure documentation shows tumor proximity to organs at risk (brain stem, spinal cord, cochlea, eye structures) and that 3D conformal radiotherapy planning cannot meet dose-volume constraints. For hippocampal-avoiding IMRT, verify brain metastases are outside 5mm margin of hippocampus and patient has expected survival ≥4 months. Update prior authorization requests to include radiation tolerance dose calculations and evidence that 3D-CRT would exceed tolerance thresholds.